Bednarski Tomasz, Olichwier Adam, Opasinska Agnieszka, Pyrkowska Aleksandra, Gan Ana-Maria, Ntambi James M, Dobrzyn Pawel
Laboratory of Molecular Medical Biochemistry, Nencki Institute of Experimental Biology, Polish Academy of Sciences, Warsaw, Poland.
Laboratory of Cell Signaling and Metabolic Disorders, Nencki Institute of Experimental Biology, Polish Academy of Sciences, Warsaw, Poland.
Biochim Biophys Acta. 2016 Dec;1861(12 Pt A):2029-2037. doi: 10.1016/j.bbalip.2016.10.005. Epub 2016 Oct 15.
Stearoyl-CoA desaturase 1 (SCD1) has recently been shown to be a critical control point in the regulation of cardiac metabolism and function. Peroxisome proliferator-activated receptor α (PPARα) is an important regulator of myocardial fatty acid uptake and utilization. The present study used SCD1 and PPARα double knockout (SCD1/PPARα) mice to test the hypothesis that PPARα is involved in metabolic changes in the heart that are caused by SCD1 downregulation/inhibition. SCD1 deficiency decreased the intracellular content of free fatty acids, triglycerides, and ceramide in the heart of SCD1 and SCD1/PPARα mice. SCD1 ablation in PPARα mice decreased diacylglycerol content in cardiomyocytes. These results indicate that the reduction of fat accumulation in the heart associated with SCD1 deficiency occurs independently of the PPARα pathway. To elucidate the mechanism of the observed changes, we treated HL-1 cardiomyocytes with the SCD1 inhibitor A939572 and/or PPARα inhibitor GW6471. SCD1 inhibition decreased the level of lipogenic proteins and increased lipolysis, reflected by a decrease in the content of adipose triglyceride lipase inhibitor G0S2 and a decrease in the ratio of phosphorylated hormone-sensitive lipase (HSL) at Ser565 to HSL (pHSL[Ser565]/HSL). PPARα inhibition alone did not affect the aforementioned protein levels. Finally, PPARα inhibition decreased the phosphorylation level of 5'-adenosine monophosphate-activated protein kinase, indicating lower mitochondrial fatty acid oxidation. In summary, SCD1 ablation/inhibition decreased cardiac lipid content independently of the action of PPARα by reducing lipogenesis and activating lipolysis. The present data suggest that SCD1 is an important component in maintaining proper cardiac lipid metabolism.
硬脂酰辅酶A去饱和酶1(SCD1)最近被证明是心脏代谢和功能调节中的一个关键控制点。过氧化物酶体增殖物激活受体α(PPARα)是心肌脂肪酸摄取和利用的重要调节因子。本研究使用SCD1和PPARα双敲除(SCD1/PPARα)小鼠来检验PPARα参与由SCD1下调/抑制引起的心脏代谢变化这一假说。SCD1缺乏降低了SCD1和SCD1/PPARα小鼠心脏中游离脂肪酸、甘油三酯和神经酰胺的细胞内含量。在PPARα小鼠中敲除SCD1可降低心肌细胞中的二酰基甘油含量。这些结果表明,与SCD1缺乏相关的心脏脂肪积累减少独立于PPARα途径发生。为了阐明观察到的变化的机制,我们用SCD1抑制剂A939572和/或PPARα抑制剂GW6\471处理HL-1心肌细胞。SCD1抑制降低了生脂蛋白水平并增加了脂肪分解,这表现为脂肪甘油三酯脂肪酶抑制剂G0S2含量降低以及丝氨酸565处磷酸化激素敏感性脂肪酶(HSL)与HSL的比率降低(pHSL[Ser565]/HSL)。单独抑制PPARα并不影响上述蛋白质水平。最后,PPARα抑制降低了5'-腺苷单磷酸激活蛋白激酶的磷酸化水平,表明线粒体脂肪酸氧化降低。总之,SCD1敲除/抑制通过减少脂肪生成和激活脂肪分解,独立于PPARα的作用降低了心脏脂质含量。目前的数据表明,SCD1是维持心脏脂质代谢正常的重要组成部分。